Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Lyell Immunopharma, Inc.

Bank of America Securities analyst Jason Zemansky reiterated a Sell rating on Lyell Immunopharma today and set a price target of $12.00. According ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LYEL	$13.58	-2.65%	47.57K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LYEL	$13.58	-2.7%	47.57K
3
4
5
6

LYEL

Get Lyell Immunopharma, Inc. Data in Excel

Get Lyell Immunopharma, Inc. Data in Excel